PCNA and neoplasm: Like sorafenib, oral administration of fisetin monotherapy significantly inhibited the tumor growth of BRAF-mutated melanoma cells in nude mice by inhibiting tumor cell proliferation markers (PCNA, Ki67 and cyclin D1).